Journals / Türk Biyokimya Dergisi / 2019 / Cilt: 44 - Sayı: 2

Influence of pegylated interferon and ribavirin on insulin resistance and metabolic factors in chronic hepatitis C

Kronik hepatit C’de pegile interferon ve ribavirinin insulin direnci ve metabolik faktörler üzerine etkisi

Pages
170–176
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this context, it can be advocatedthat insulin resistance at week 48 may be a predictive factor for prediction of SVR at week 72.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In this study it was aimed to evaluate theeffect of pegylated interferon alfa-2a/2b and ribavirin,which are used for treatment of chronic hepatitis C (CHC),on insulin resistance and metabolic factors.Materials and methods: A total of 104 CHC patients aged20–75 years with available serum insulin data at 0 and48 weeks, and hepatitis C virus (HCV)-RNA data at 0, 12, 24,48 and 72 weeks were included in the study.
📊
Key Findings & Data:All clinical parameters were assessed according to the therapy response.Results: Among 104 patients, sustained virologic response(SVR) was achieved in 55 cases.
💡
Conclusion & Impact:In this context, it can be advocatedthat insulin resistance at week 48 may be a predictive factor for prediction of SVR at week 72.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: In this study it was aimed to evaluate theeffect of pegylated interferon alfa-2a/2b and ribavirin,which are used for treatment of chronic hepatitis C (CHC),on insulin resistance and metabolic factors.Materials and methods: A total of 104 CHC patients aged20–75 years with available serum insulin data at 0 and48 weeks, and hepatitis C virus (HCV)-RNA data at 0, 12, 24,48 and 72 weeks were included in the study. All clinical parameters were assessed according to the therapy response.Results: Among 104 patients, sustained virologic response(SVR) was achieved in 55 cases. A statistically significantdifference was noted between SVR and non-SVR groupsregarding γ-glutamyltranspeptidase (GGT), insulin level plushomeostasis model assessment (HOMA) score and insulinresistance at week 48, log HCV-RNA and stage of fibrosis.Conclusion: Insulin resistance is accepted to have a negative effect on SVR. Insulin resistance may improve onceSVR is achieved. Presence of IR at week 48 has been foundassociated with SVR. In this context, it can be advocatedthat insulin resistance at week 48 may be a predictive factor for prediction of SVR at week 72.

Özet

Amaç: Bu çalışmada, kronik hepatit C tedavisinde kullanılan pegile interferon alfa 2a/2b ve ribavirinin insulin direnci ve metabolik faktörler üzerine etkileri incelenmiştir. Materyal ve Metotlar: Çalışmaya yaşları 20 ile 75 arasında değişen, 0 ve 48. haftalara ait insulin değerleri ile birlikte 0, 12, 24, 48 ve 72. haftalardaki HCV-RNA değerleri mevcut olan toplam 104 kronik hepatit C hastası dahil edilmiştir. Tüm klinik parametreler tedavi yanıtına göre değerlendirilmiştir. Bulgular: Kalıcı virolojik yanıt (KVY) 104 hastanın 55’inde elde edilebilmiştir. KVY elde edilen ve edilemeyen gruplar arasında GGT, HCV-RNA düzeyi, fibrozis evresi ve 48. haftadaki insulin düzeyi, insulin direnci ve HOMA skoru arasında istatistiksel olarak anlamlı ilişki tespit edilmiştir. Sonuç: İnsulin direncinin KVY üzerinde negatif etkisi olduğu kabul edilmektedir. SVR elde edildiğinde ise insulin direnci düzelebilmektedir. İnsülin direncinin 48. haftadaki varlığı, KVY ile ilişkili bulunmuştur. Bu bağlamda; 48. haftada mevcut olan insulin direncinin, 72. haftadaki KVY konusunda öngördürücü olacağı söylenebilir.

🔖

Cite This Article

ASLAN, F., ÜNSAL, B., KOYUNCU, B., ALTIN, Z., ÇOLAK, A., ÖZER, S., DİNİZ, G. (2022). Influence of pegylated interferon and ribavirin on insulin resistance and metabolic factors in chronic hepatitis C. Türk Biyokimya Dergisi, Cilt: 44 - Sayı: 2, 170–176. https://ajindex.com/articles/620884

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Marcellin P. Management of patients with viral hepatitis. Paris, France: APHC
  2. Consensus Conference. Treatment of hepatitis C. Guidelines. Gastroenterol Clin Biol 2002;26:B312–20
  3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82
  4. Cornberg M, Manns MP, Wedemeyer H. Hepatitis C, standard of care. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, editors. Hepatology, a clinical textbook. Germany: Flying Publisher, 2009, pp. 183–98
  5. Grace MJ, Bordens RW, Cutler DL. Peginterferons for the treatment of chronic hepatitis C. Hepatol Rev 2005;2:3–9
  6. Aspinall RJ, Pockros PJ. Review article: the management of side effects during therapy for hepatitis C. Aliment Pharmacol Ther 2004;20:917–29
  7. Thomas DL, Lemon SM. Hepatitis C. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 6th ed. Philadelphia: Churchill Livingstone, 2005, pp. 1950–81
  8. Cãruntu FA, Benea L. Acute hepatitis C virus infection: diagnosis, pathogenesis, treatment. J Gastrointestin Liver Dis 2006;15:249–56
  9. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol 2007;13:2461–6
  10. Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT; ACTG A5178 Study Team. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study. Clin Infect Dis 2012;55:631–8
  11. Chien CH, Lin CL, Hu CC, Chang JJ, Chien RN. Clearance of hepatitis C virus improves insulin resistance during and after peginterferon and ribavirin therapy. J Interferon Cytokine Res 2015;35:981–9
  12. Ozaras R, Tahan V. Acute hepatitis C: prevention and treatment. Expert Rev Anti-infect Therap 2009;7:351–61
  13. Velt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677–84
  14. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433–44
  15. Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, et al. Telaprevir